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In vivo dosimetry using electron paramagnetic resonance in
L-alanine in gynecological low dose rate brachytherapy
Katarzyna Schultka1, Bart∏omiej Ciesielski1, Krystyna Serkies2,
Barbara Wysocka2, Tomasz Sawicki2, Zofia Tarnawska2, Jacek Jassem2
O b j e c t i v e s.  to present the results of in vivo dosimetry performed on 15 patients treated for gynecological cancer with the aim
of optimizing the detector design and its application in body cavites and comparing the doses measured in vivo with those
calculated by the Plato (Nucletron) system of brachytherapy treatment planning.
M a t e r i a l  a n d  m e t h o d s.  Electron paramagnetic resonance (EPR) is, as a dosimetric method, based on the detection of
free radicals generated by ionizing radiation in L-alanine. The concentration of free radicals is proportional to the absorbed
dose and is determined by the EPR technique. The detectors appear as small cellulose capsules (outer diameter 5 mm,
length 15 mm), tightly filled with crystalline L-alanine powder. The doses from 137Cs brachytherapy sources were measured in
selected points inside the rectum and vagina.
R e s u l t s.  The relative deviations of measured doses from those calculated by the treatment planning system ranged from 
-28% to +40%. The mean deviations from the prescribed doses were relatively low (+1% for detectors placed in the rectum,
– 10% for detectors placed in the vagina). However, due to a low number of samples and large standard deviations of the mean
values (±23% and ±11% for detectors placed in the rectum and the vagina, respectively), the deviations of the mean
values are of low statistical significance. The accuracy of the measurements was analyzed and is hereby discussed.
C o n c l u s i o n s.  The main sources of the differences between the measured and calculated dose should, generally, be
attributed to uncertainties in the determination of the detector position inside the body as ascertained from the radiographs and
to uncontrollable motion of detectors during treatment.
Dozymetria in vivo metodà spektroskopii EPR alaniny w brachyterapii ginekologicznej
C e l.  W pracy przedstawiono u˝ycie dozymetrii in vivo metodà spektroskopii elektronowego rezonansu paramagnetycznego
(EPR) L-alaniny w brachyterapii ginekologicznej oraz optymalizacj´ budowy detektorów i ich umieszczania we wn´kach cia∏a
pacjentki.
M a t e r i a ∏ y  i m e t o d y.  Technika EPR oparta jest na wykrywaniu stabilnych wolnych rodników wytwarzanych przez
promieniowanie jonizujàce w materiale dozymetru. Liczba rodników generowana w jednostce masy detektora jest
proporcjonalna do poch∏oni´tej dawki promieniowania. Zastosowano dozymetry alaninowe w postaci kapsu∏ek o Êrednicy
zewn´trznej 5 mm i d∏ugoÊci 15 mm, wype∏nionych sproszkowanà krystalicznà L-alaninà. Wyniki pomiarów in vivo
porównano z wartoÊciami dawki obliczonej za pomocà systemu planowania PLATO firmy Nucletron.
W y n i k i.  Rozbie˝noÊci pomi´dzy dawkami planowanymi i zmierzonymi zawarte by∏y w granicach od -28% do +40%. Ârednie
odchylenie by∏o niewielkie (+1% dla detektorów umieszczonych w odbytnicy, -10% dla detektorów umieszczonych w pochwie),
jednak˝e z powodu ma∏ej iloÊci próbek i stosunkowo wysokiego odchylenia standardowego (odpowiednio ±23% i ±11% dla
detektorów umieszczonych w odbytnicy i w pochwie) odchylenia Êrednich wartoÊci nie sà istotnà statystycznie miarà zgodnoÊci
pomi´dzy dawkami zmierzonymi a obliczonymi.
W n i o s k i.  Za g∏ównà przyczyn´ rozbie˝noÊci pomi´dzy dawkà zmierzonà i obliczonà uznano niepewnoÊç okreÊlenia
po∏o˝enia detektorów wewnàtrz cia∏a i ich przemieszczanie si´ w czasie trwania terapii.
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Introduction
The effect of radiotherapy depends on the precision of
delivery of the prescribed dose to the target volume. The
accuracy of dose delivery is a crucial issue in radiotherapy.
The difference between planned and actually delivered
doses may decrease the probability of tumor control or
increase the risk of post-radiation complications. In
gynecologic brachytherapy the critical organs include
the rectum and the urinary bladder. Late complications
from these two organs may significantly decrease the
patients’ quality of life. The International Commission
on Radiation Units and Measurements (ICRU) recom-
mended the use of a 60% isodose as the reference target
volume for intracavitary therapy in gynecological cancer
[1].
One of the dosimetric methods used both in
teletherapy [2-7] and brachytherapy [8-10] is EPR/alanine
dosimetry. The advantages of the alanine detector include
water equivalence, flat energy dependence and non-
destructive readout. We have recently published
a feasibility study on applications of EPR/alanine
dosimetry in external beam radiotherapy [5]. In the
present study we present our preliminary results of in
vivo measurements using EPR/alanine dosimetry in
gynecologic brachytherapy.
Material and methods
The detectors were applied in 15 gynecological cancer patients
(7 cases of cervical cancer and 8 cases of endometrial cancer)
treated with low-dose rate (LDR) brachytherapy (Selectron,
Nucletron, The Netherlands) in the Department of Oncology
and Radiotherapy, Medical University of Gdansk (MUG). Three
patients were treated with definite irradiation and 12 patients
underwent postoperative radiotherapy. In all fifteen cases only
vaginal ovoids were employed. The dose distribution in the
pelvic region was calculated with a computer planning system
(PLATO – Nucletron, The Netherlands) after applicator
insertion. The positions of the detectors (placed in the rectum
and in the vagina) were determined using AP and lateral
orthogonal radiographs. The Selectron LDR/MDR (Nucletron,
The Netherlands) afterloading radiation system containing 137Cs
sources was used in all cases.
The detectors had a form of small cellulose capsules
(external diameter 5 mm; length 15 mm) filled with 0.5 g of
alanine powder (SIGMA Chemical Company). The capsules
were sealed in waterproof Parafilm pockets.
Three methods of detector application were used in this
study. In the first, the detectors replaced a flexible lead wire
one marker inserted into the rectum. Six alanine detectors were
placed in the main channel of a Foley’s catheter. Inside the
second, thinner channel a lead wire (1 mm in diameter) was
placed in order to visualize the catheter on radiographs
(Figure 1). The catheter was then sealed in a 0.2 mm thick
waterproof polyethylene foil and placed in the rectum (instead of
the routinely used lead wire marker – Figure 3). The other two
methods were used for in vivo dosimetry within the vagina. In the
second method, the capsules sealed in waterproof foil were
wrapped around with a few coils of radio-opaque thread and
then placed in the vagina (Figure 2a). The third application
method used capsules fitted to an oval frame made of 1 mm
steel (Figure 2b). The capsules with the steel frame were sealed
in a waterproof foil pocket and placed in the vagina after the
ovoid application.
The doses were calculated at the center of the dosimeter
with a computer planning system. The geometry of the detector
position was reconstructed from two orthogonal radiographs.
EPR measurements were performed in the Department
of Physics and Biophysics of the MUG. After irradiation, the
alanine powder was transferred into an EPR quartz tube and the
dosimetric signal was measured with a Varian E-4 spectrometer
at 5 mW microwave power, 1.25 mT modulation amplitude.
These spectrometer parameters were previously determined as
giving the optimal signal-to-noise ratio [4-5]. All readings were
normalized with regard to spectrometer gain and linear packing
density of powder inside the quartz tube [4-5].
The efficiency of free radicals generation depends on the
temperature during irradiation [11]. Because the temperature of
the detectors located inside the body cavities differed from the
temperature used during the calibration procedure (performed
at 23°C) a temperature correction factor k(T) calculated
according to data of Nagy et al. [11] was introduced. The
temperature corrected intensities of the EPR signals were
converted to dose using a reference alanine sample irradiated
with 60Co to the dose of 72 Gy. The linear response of the
dosimetric EPR signal in this dose range was demonstrated in
our previous reports [4-5]. Given the difference in the radiation
quality between the in vivo irradiated detectors (662 keV γ rays)
and the reference alanine sample (1.25 MeV γ rays), a correc-
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Figure 1. A schematic diagram of detectors placed inside Foley’s
catheter
Figure 2a
Figure 2. Radiographs of detectors placed in the vagina. The diagrams beside the radiographs show the placement of the radio-opaque thread
(Figure 2a) and the steel frame (Figure 2b), which allow to localize the detectors on the radiographs
Figure 2b
tion factor accounting for differences in mass absorption
coefficients at those two energies [12] was additionally
introduced in the dose calculations.
Results
The differences between the measured and the calculated
doses for all three application methods are given in Table
I. For the six detectors placed in the rectum the
differences between the measured and the planned doses
varied from -25% to +40%, depending on the localization
of the dosimeters. For the eight patients who had
detectors with radio-opaque thread placed in the vagina,
the differences varied between -28% and -1%. For doses
measured using detectors with a steel frame the deviations
varied from -23% to 14%. The third method (with steel-
frame detectors) resulted in the best visualization of
the detectors on radiographs, as shown in Figures 2 and 3.
Discussion
Detectors used for in vivo dosimetry should not interfere
with the therapeutic process. In addition, the detector
should be well visualized on radiographs and should
maintain stable position during the planning process and
treatment delivery. Our results of in vivo dosimetry in
the rectum (samples no. 1-6 in Table I) show certain
systematic differences between the measured and the
planned doses. These differences can be explained by
a shift in catheter position during treatment delivery from
its original location assumed for dose calculations, i.e.
the rotation of the whole catheter in such a way, that the
detectors no. 2 and 3 were shifted towards the applicator
and detectors no. 5 and 6 moved away from the applicator
(Figure 3). This change in positions might have been
caused by intestinal movements and involuntary patient
movements.
Of the three methods used in this study, two were
used only for in vivo dosimetry in the vagina. The radio-
opaque thread did not allow for a precise determination
of detector position – mainly due to the poor quality of
the radiographs used for the verification of their locations
in the vagina. The use of “steel-frame detectors” (the
third method of application) caused a significant
improvement in the precise localization of detectors on
radiographs. However, this did not offer considerable
improvement in the difference between the planned and
the measured dose. In our previous studies using
EPR/alanine dosimetry in external beam radiotherapy
[4-5] errors of the EPR signal measurements reached
approximately 2-3% for doses at the level of a few Gy.
Therefore, the much greater differences demonstrated
here for dosimetry in brachytherapy cannot be attributed
to the uncertainty of EPR measurements or to the
determination of actual dose absorbed in the detectors.
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Figure 3. Radiographs with detectors placed in the rectum. Black
points indicate the localization of the center of the detector
Table I. Results of in vivo dosimetry in the rectum and in the vagina using three methods of application of the detectors. 
The method of detector visualization on the radiographs is given in the last column. 
The sample numbers (column 2) refer to their positions shown in Figure 3. Dmeas and Dpl stand for measured and planned dose, 
respectively. ROT denotes data obtained in detectors with radio-opaque thread, and SF denotes detectors in a steel frame
Case Sample number Planned dose [Gy] (Dmeas - Dpl)/ Dpl Visualization method
1 1 9.7 0% catheter
1 2 15.7 40% catheter
1 3 15.2 15% catheter
1 4 10.1 -6% catheter
1 5 6.8 -25% catheter
1 6 4.2 -16% catheter
2 29.2 -4% ROT
3 30.0 -4% ROT
4 31.4 -1% ROT
5 43.5 -8% ROT
6 44.5 -24% ROT
7 45.7 -9% ROT
8 45.7 -28% ROT
9 56.1 -7% ROT
10 15.7 -23% SF
11 16.8 -9% SF
12 25.0 14% SF
13 38.9 -7% SF
14 46.0 -18% SF
15 62.7 -16% SF
The main source of the observed discrepancies seems to
be related to two factors. The first one is the uncertain
three-dimensional localization of the detectors within the
body, and the other – the steep gradient of doses typical
for brachytherapy, which causes significant changes in
the readout doses with small deviations of the assumed vs.
actual position of the measurement point. For example,
the shift in the detector position of approx. 1 mm, which is
plausible in the in vivo conditions, may cause a change in
the dose readout ranging from 10% to 20% (depending
on particular isodose distribution and detector location).
In addition, the errors can vary with the detector
size and its orientation (parallel or orthogonal) with
respect to isodose distribution. The dose which was
calculated (Dpl) using the computerized planning system
refers to a point, while the measured dose (Dmeas) refers
to an average value over the entire dosimeter volume.
Qualitatively, the importance of this effect is illustrated in
Figure 4, in which the detector contour is superimposed
on a typical 137Cs spatial isodose distribution.
Preliminary in vivo dosimetry results reported by
other authors confirm our notion that a precise
positioning of the detectors and their size are of
paramount importance for the final accuracy of dosimetry
[9,10]. The use of smaller alanine detectors (3-4 mm)
firmly fixed to the applicator wall [9] or to the patient
mould [10] allows for smaller discrepancies between the
calculated and the planned doses (up to 10%-13 %)
despite a similar precision of the EPR signal readout 
(2-5%).
Conclusions
Currently, EPR/alanine in vivo dosimetry applied for
intracavitary brachytherapy allows for only a rough
estimate of the actual absorbed dose. The lack of
precision in detector localization, usually based on
radiographs and unavoidable detector shifts during
treatment process are the main causes limiting the
accuracy of in vivo measurements. Further improvement
in the experimental verification of the planned brachy-
therapy doses can be achieved if the problems of
reduction of the dosimeters size and their precise, three
dimensional localization are solved. At present, it remains
impossible to prevent movements of the detectors inside
the body during the several hours of the LDR treatment
session.
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Figure 4. Contours of the alanine detector on the top of an exemplary
isodose distribution. The arrows indicate isodoses appropriate to
selected doses given in the frame
